Neuroblastoma is the most common solid tumor found outside the brain in children, and nearly half of patients are diagnosed after the disease has already spread. For these high-risk cases, treatment has traditionally involved an intensive combination of chemotherapy, stem-cell transplant, and follow-up therapy to target any remaining cancer cells. In recent years, the addition of an antibody called ch14.18—which targets a marker called GD2 found on neuroblastoma cells—helped improve two-year event-free survival by about 20 percent. Still, more than a third of high-risk patients are not cured by this approach, underscoring the need for continued innovation.
A new pilot Phase II clinical trial is now investigating whether introducing a related but distinct antibody, hu14.18K322A, earlier in the treatment process—during the initial induction chemotherapy phase—could further improve outcomes. This antibody also targets the GD2 marker, which is consistently present on neuroblastoma cells, making it an attractive target for precision-focused treatment. In this study, the antibody is combined with two established chemotherapy drugs, cyclophosphamide and topotecan, along with GM-CSF, a supportive therapy that helps boost immune cell activity.
The trial’s design reflects a thoughtful, multi-pronged approach to a complex disease. Researchers aim to measure how well this combination shrinks tumors early in treatment and whether it extends event-free survival for newly diagnosed patients. They are also examining the feasibility of using the antibody across a longer, six-course induction period, and studying whether advanced radiation techniques—such as intensity-modulated or proton beam therapy—can improve local tumor control in the abdomen, a common site for these tumors.
Additional components of the study explore how the antibody performs when paired with immune-boosting strategies, including allogeneic natural killer (NK) cells donated by a parent shortly after stem-cell transplant, as well as combinations with interleukin-2 during the minimal residual disease phase. These secondary objectives reflect a broader effort to understand how immune-based therapies might work together to give the body additional tools to fight remaining cancer cells after the initial treatment phases.
While outcomes for high-risk pediatric neuroblastoma remain challenging, this kind of research represents meaningful progress in refining and personalizing treatment for one of childhood cancer’s most difficult forms. By building on the success of earlier antibody therapies and testing new combinations and timing strategies, researchers are working to close the gap for patients who don’t respond fully to current standards of care. This information is for informational purposes only and is not medical advice.
Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.
Source: Clinical Trial: Therapy for Children With Advanced Stage Neuroblastoma
Leave a Reply